The thesis

Boston Scientific operates in the medical devices space with 7.5% YoY revenue growth. The company's high gross margin of 71.6% and net margin of 17.47% indicate strong profitability. Despite a 'BUY' analyst consensus rating, the conviction score is relatively low at 14/100, suggesting underlying uncertainty. The company's positioning in the healthcare sector exposes it to risks such as drug pricing policy changes.

Why now

The current macro context, with elevated energy prices and bond yields driving expectations of tighter monetary policy, may impact consumer discretionary spending and indirectly affect healthcare spending. Boston Scientific's revenue growth and high margins make it an interesting watch amidst this uncertainty.

What to watch

Investors should monitor Boston Scientific's upcoming revenue growth trajectory and margin stability over the next few quarters. Any significant changes in drug pricing policy or major trial outcomes will be critical in determining the company's future performance.

Key risks

The company faces risks from drug pricing policy changes and trial failures, which are recurring shocks to the healthcare sector. A valuation risk is also present, given the P/E ratio of 17.7x and potential for market revaluation amid changing macroeconomic conditions.

Theme exposure